A new study published in dinvestigated the association between serum levels of Meteorin-like (Metrnl) – a novel adipomyokine that may improve glucose tolerance and affect insulin resistance, with blood glucose status and to its association with insulin resistance. This study entailed measuring of serum levels of Metrnl of the participants through enzyme-linked immunosorbent assay (ELISA). The study included 40 subjects with normal glucose tolerance (NGT); 40 with impaired fasting glucose (IFG); 40 with impaired glucose tolerance (IGT); and 40 newly diagnosed type 2 diabetes mellitus (T2DM) patients. The relationship between serum levels of Metrnl and metabolic parameters was assessed. The findings showed that serum levels of Metrnl was highest in patients with T2DM and significantly increased in patients with prediabetes than in individuals with NGT. Additionally, serum Metrnl level significantly correlated to lipid profile, glucose profile, and insulin resistance. Moreover, Metrnl significantly increased the risk of T2DM before adjusting for the homeostatic model assessment of insulin resistance (HOMA-IR). On the other hand, when further adjusted for HOMA-IR, Metrnl was no longer associated with an increased OR for T2DM, while the HOMA-IR significantly increased the risk of T2DM. From the results, it was concluded that serum levels of Metrnl were significantly increased in patients with T2DM and may increase the risk of T2DM independent of insulin resistance.